Biofrontera Inc. (BFRI): Total Liabilities
$18.08M
As of 2025-12-31
$18.11M
As of 2026-06-30
-12.5%
3-year compound annual growth
-0.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.08M | +2.4% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $17.67M | -23.6% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $23.14M | -14.3% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $27.01M | -35.5% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $41.88M | +128.7% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $18.31M | n/a | 2022-04-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Biofrontera Inc. (BFRI) | 2025-12-31 | $18.08M | +2.4% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $112.27M | -16.7% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $7.67M | +67.3% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $41.92M | +370.4% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
Compare BFRI, WVE, XLO, INBP side by side · Screen every company in Pharmaceutical Preparations ↗